- Home
- Automated
- List of product information
- PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL [SIN15801P]
PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL [SIN15801P]
Active ingredients: PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL
Last updated 26 October 2025
On this page
Product Info
PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL
[SIN15801P]
Product information
Active Ingredient and Strength | PANDEMIC INFLUENZA VIRUS TYPE A, INACTIVATED AND DISRUPTED - 30 MCG HA/0.5 ML |
Dosage Form | INJECTION, SUSPENSION |
Manufacturer and Country | SEQIRUS PTY LTD - AUSTRALIA |
Registration Number | SIN15801P |
Licence Holder | SEQIRUS PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07BB02 |
Therapeutic indications
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with Singaporean Health Authorities’ recommendations, taking into account the recommendation of the World Health Organisation.
Dosage and method of administration
Dose
Two 0.5 mL doses, 21 days apart.
Method of administration
The vaccine should be administered by intramuscular injection.
The vaccine should be allowed to reach room temperature before use. Shake before use. The vaccine should appear as a homogeneous creamy/white opaque liquid suspension with no large clumps visible.
Once opened, the vaccine is to be used immediately and within the one vaccination session, with any remaining contents discarded in accordance with local requirements. No additions should be made to the contents of the vial.
Instructions for use and handling
It is important that the contents of the container be shaken thoroughly immediately before use. The vaccine should appear as a homogenous creamy/white opaque liquid suspension with no large clumps visible.
Contraindications
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (e.g. eggs, chicken protein refer to sections Qualitative and Quantitative Composition and List of excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) of this vaccine. However, in a pandemic situation, it may be appropriate to give the vaccine, provided that facilities for resuscitation are immediately available in case of need.